{
    "xml": "<topic id=\"PHP3560\" outputclass=\"drug\" rev=\"1.11\" type=\"drug\" namespace=\"/drugs/colistimethate-sodium\" basename=\"colistimethate-sodium\" title=\"COLISTIMETHATE SODIUM\">\n<title>COLISTIMETHATE SODIUM</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_190\" namespace=\"/interactions/list-of-drug-interactions/antibacterials/polymyxins/colistimethate-sodium\">Colistimethate Sodium</xref>\n</p>\n<data name=\"vtmid\">73074003</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_586806521\" title=\"Polymyxin antibacterials\">Polymyxin antibacterials</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n<p outputclass=\"synonyms\">Colistin sulfomethate sodium</p>\r\n</body>\n<topic id=\"PHP66160\" outputclass=\"drugAction\" rev=\"1.13\" parent=\"/drugs/colistimethate-sodium\">\n<title>Drug action</title>\n<body>\n<section>\n<sectiondiv>\n<p>The polymyxin antibiotic, <b>colistimethate sodium</b> (colistin sulfomethate sodium), is active against Gram-negative organisms including <ph outputclass=\"organism\">\n<i>Pseudomonas aeruginosa</i>\n</ph>, <ph outputclass=\"organism\">\n<i>Acinetobacter baumanii</i>\n</ph>, and <ph outputclass=\"organism\">\n<i>Klebsiella pneumoniae</i>\n</ph>. It is not absorbed by mouth and thus needs to be given by injection for a systemic effect.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP66106\" outputclass=\"indicationsAndDose\" rev=\"1.56\" parent=\"/drugs/colistimethate-sodium\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Gram-negative infections resistant to other antibacterials, including those caused by <ph outputclass=\"organism\">\n<i>\n<i>Pseudomonas aeruginosa</i>\n</i>\n</ph>, <ph outputclass=\"organism\">\n<i>\n<i>Acinetobacter baumanii</i>\n</i>\n</ph> and <ph outputclass=\"organism\">\n<i>\n<i>Klebsiella pneumoniae</i>\n</i>\n</ph>\n</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By slow intravenous injection or by intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult (body-weight up to 59 kg)</p>\n<p>50&#8239;000&#8211;75&#8239;000&#8239;units/kg daily in 3 divided doses, to be administered into a totally implantable venous access device when giving via slow intravenous injection.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Adult (body-weight 60 kg and above)</p>\n<p>1&#8211;2&#8239;million units every 8&#8239;hours, to be administered into a totally implantable venous access device when giving via slow intravenous injection.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Adjunct to standard antibacterial therapy for <ph outputclass=\"organism\">\n<i>\n<i>Pseudomonas aeruginosa</i>\n</i>\n</ph> infection in cystic fibrosis</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By inhalation of nebulised solution</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>1&#8211;2&#8239;million units twice daily; increased to 2&#8239;million units 3 times a day, dose only to be increased for subsequent respiratory isolates of <i>\n<i>Pseudomonas aeruginosa</i>\n</i>.</p>\n</li>\n</ul>\n<p outputclass=\"routesOfAdministration\">By inhalation of powder</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>1.66&#8239;million units twice daily.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP66172\" outputclass=\"contraindications\" rev=\"1.7\" parent=\"/drugs/colistimethate-sodium\">\n<title>Contra-indications</title>\n<body>\n<section outputclass=\"contraindications\">\n<p>\n<ph outputclass=\"contraindication\">Myasthenia gravis</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP66200\" outputclass=\"cautions\" rev=\"1.16\" parent=\"/drugs/colistimethate-sodium\">\n<title>Cautions</title>\n<body>\r\n<section outputclass=\"cautions\">\r\n<title>General cautions:</title>\r\n<p>\r\n<ph outputclass=\"caution\">\r\n<xref format=\"dita\" href=\"#PHP78608\" type=\"bookmark\" namespace=\"/treatment-summaries/acute-porphyrias\">Acute porphyrias</xref>\r\n</ph>\r\n</p>\r\n<sectiondiv outputclass=\"additionalCautions\">\r\n<p outputclass=\"title\">Specific cautions:</p>\r\n<sectiondiv outputclass=\"cautionsOrContraindicationsWithRoutes\">\r\n<p outputclass=\"title\">When used by inhalation</p>\r\n<p>\r\n<ph outputclass=\"caution\">severe haemoptysis&#8212;risk of further haemorrhage</ph>\r\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\r\n\r\n\r\n\r\n\r\n\r\n\r\n</body>\n</topic>\n<topic id=\"PHP66103\" outputclass=\"interactions\" rev=\"1.8\" parent=\"/drugs/colistimethate-sodium\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (polymyxins).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP66062\" outputclass=\"sideEffects\" rev=\"1.14\" parent=\"/drugs/colistimethate-sodium\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"specificSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"commonOrVeryCommon\">\n<p outputclass=\"title\">Common or very common</p>\n<sectiondiv outputclass=\"sideEffectsWithRoutes\">\n<p outputclass=\"title\">When used by inhalation</p>\n<p>\n<ph outputclass=\"sideEffect\">bronchospasm</ph>; <ph outputclass=\"sideEffect\">cough</ph>; <ph outputclass=\"sideEffect\">dysphonia</ph>; <ph outputclass=\"sideEffect\">nausea</ph>; <ph outputclass=\"sideEffect\">sore mouth</ph>; <ph outputclass=\"sideEffect\">Sore throat</ph>; <ph outputclass=\"sideEffect\">taste disturbances</ph>; <ph outputclass=\"sideEffect\">vomiting</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n<sectiondiv outputclass=\"uncommon\">\n<p outputclass=\"title\">Uncommon</p>\n<sectiondiv outputclass=\"sideEffectsWithRoutes\">\n<p outputclass=\"title\">When used by inhalation</p>\n<p>\n<ph outputclass=\"sideEffect\">hypersalivation</ph>; <ph outputclass=\"sideEffect\">thirst</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n<sectiondiv outputclass=\"rare\">\n<p outputclass=\"title\">Rare</p>\n<sectiondiv outputclass=\"sideEffectsWithRoutes\">\n<p outputclass=\"title\">With intravenous use</p>\n<p>\n<ph outputclass=\"sideEffect\">vasomotor instability</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<sectiondiv outputclass=\"sideEffectsWithRoutes\">\n<p outputclass=\"title\">With intravenous use</p>\n<p>\n<ph outputclass=\"sideEffect\">apnoea</ph>; <ph outputclass=\"sideEffect\">confusion</ph>; <ph outputclass=\"sideEffect\">headache</ph>; <ph outputclass=\"sideEffect\">muscle weakness</ph>; <ph outputclass=\"sideEffect\">nephrotoxicity</ph>; <ph outputclass=\"sideEffect\">neurotoxicity reported especially with excessive doses</ph>; <ph outputclass=\"sideEffect\">perioral paraesthesia</ph>; <ph outputclass=\"sideEffect\">peripheral paraesthesia</ph>; <ph outputclass=\"sideEffect\">psychosis</ph>; <ph outputclass=\"sideEffect\">rash</ph>; <ph outputclass=\"sideEffect\">slurred speech</ph>; <ph outputclass=\"sideEffect\">vertigo</ph>; <ph outputclass=\"sideEffect\">visual disturbances</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</sectiondiv>\n</section>\n<section outputclass=\"sideEffectsAdvice\">\n<title>Side-effects, further information</title>\n<sectiondiv>\n<p outputclass=\"title\">Dose-related side-effects</p>\n<p>The major adverse effects are dose-related neurotoxicity and nephrotoxicity.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP66098\" outputclass=\"pregnancy\" parent=\"/drugs/colistimethate-sodium\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p outputclass=\"specificity\">When used by <ph outputclass=\"route\">inhalation</ph>\n</p>\n<p>Clinical use suggests probably safe.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">intravenous</ph> use</p>\n<p>Use only if potential benefit outweighs risk.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP66220\" outputclass=\"breastFeeding\" parent=\"/drugs/colistimethate-sodium\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Present in milk but poorly absorbed from gut; manufacturers advise avoid (or use only if potential benefit outweighs risk).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP66082\" outputclass=\"renalImpairment\" parent=\"/drugs/colistimethate-sodium\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">intravenous</ph> use</p>\n<p>Reduce dose.</p>\n</sectiondiv>\n</section>\n<section outputclass=\"additionalMonitoringInRenalImpairment\">\n<sectiondiv>\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">intravenous</ph> use</p>\n<p>In renal impairment, monitor plasma colistimethate sodium concentration during parenteral treatment&#8212;consult product literature.</p>\n<p>Recommended &#8216;peak&#8217; plasma colistimethate sodium concentration (approx. 1 hour after intravenous injection or infusion) 5&#8211;15&#8239;mg/litre; pre-dose (&#8216;trough&#8217;) concentration 2&#8211;6&#8239;mg/litre.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP66036\" outputclass=\"monitoringRequirements\" parent=\"/drugs/colistimethate-sodium\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">intravenous</ph> use</p>\n<p>Monitor renal function.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"specificity\">When used by <ph outputclass=\"route\">inhalation</ph>\n</p>\n<p>Measure lung function before and after initial dose of colistimethate sodium and monitor for bronchospasm; if bronchospasm occurs in a patient not using a bronchodilator, repeat test using a bronchodilator before the dose of colistimethate sodium.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP66248\" outputclass=\"directionsForAdministration\" rev=\"1.21\" parent=\"/drugs/colistimethate-sodium\">\n<title>Directions for administration</title>\n<body>\n<section>\n<sectiondiv>\n<p outputclass=\"specificity\">When used by <ph outputclass=\"route\">inhalation</ph>\n</p>\n<p>Other inhaled drugs should be administered before colistimethate sodium.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">intravenous</ph> use</p>\n<p>For <i>intravenous infusion</i> (<i>Colomycin</i>\n<tm tmtype=\"reg\"/>, <i>Promixin</i>\n<tm tmtype=\"reg\"/>), give intermittently in Sodium chloride 0.9% (or Glucose 5% for <i>Promixin</i>\n<tm tmtype=\"reg\"/> brand only); dilute with 50&#8239;mL infusion fluid and give over 30 minutes.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP58354\" outputclass=\"prescribingAndDispensingInformation\" rev=\"1.12\" parent=\"/drugs/colistimethate-sodium\">\n<title>Prescribing and dispensing information</title>\n<body>\n<section>\n<sectiondiv>\n<p>Colistimethate sodium is included in some preparations for topical application.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP66092\" outputclass=\"patientAndCarerAdvice\" rev=\"1.10\" parent=\"/drugs/colistimethate-sodium\">\n<title>Patient and carer advice</title>\n<body>\n<section outputclass=\"generalPatientAdvice\">\n<sectiondiv>\n<p outputclass=\"specificity\">When used by <ph outputclass=\"route\">inhalation</ph>\n</p>\n<p>Patient should be advised to rinse mouth with water after each dose of dry powder inhalation.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP66003\" outputclass=\"nationalFunding\" rev=\"1.19\" parent=\"/drugs/colistimethate-sodium\">\n<title>National funding/access decisions</title>\n<body>\r\n<section>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisals\">\r\n<p outputclass=\"title\">NICE technology appraisals (TAs)</p>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA276</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Colistimethate sodium by dry powder inhalation for pseudomonal lung infection in cystic fibrosis (March 2013)</p>\r\n<p>Colistimethate sodium dry powder for inhalation is recommended for chronic pulmonary infection caused by <ph outputclass=\"organism\">\r\n<i>Pseudomonas aeruginosa</i>\r\n</ph> in patients with cystic fibrosis who would benefit from continued treatment, but do not tolerate the drug in its nebulised form. The manufacturer must provide colistimethate sodium dry powder for inhalation at the discount agreed as part of the patient access scheme to primary, secondary and tertiary care in the NHS. Patients currently receiving colistimethate sodium dry powder for inhalation can continue treatment until they and their clinician consider it appropriate to stop.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA276\">www.nice.org.uk/TA276</xref>\n</sectiondiv>\n</sectiondiv>\r\n </section>\r\n\r\n</body>\n</topic>\n<topic id=\"PHP3560-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/colistimethate-sodium\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n<p>Forms available from special-order manufacturers include: ear drops, oral solution</p>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75216\" title=\"Tablet\" namespace=\"/drugs/colistimethate-sodium/tablet\">Tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75245\" title=\"Powder for solution for injection\" namespace=\"/drugs/colistimethate-sodium/powder-for-solution-for-injection\">Powder for solution for injection</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75259\" title=\"Inhalation powder\" namespace=\"/drugs/colistimethate-sodium/inhalation-powder\">Inhalation powder</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75224\" title=\"Powder for nebuliser solution\" namespace=\"/drugs/colistimethate-sodium/powder-for-nebuliser-solution\">Powder for nebuliser solution</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78467\" namespace=\"/treatment-summaries/respiratory-system\" title=\"Respiratory system\" count=\"1\" rel=\"backlink\">Respiratory system</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78557\" namespace=\"/treatment-summaries/eye\" title=\"Eye\" count=\"1\" rel=\"backlink\">Eye</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_190\" namespace=\"/interactions/list-of-drug-interactions/antibacterials/polymyxins/colistimethate-sodium\" title=\"Colistimethate Sodium\" count=\"1\" rel=\"link\">Colistimethate Sodium</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78608\" namespace=\"/treatment-summaries/acute-porphyrias\" title=\"Acute porphyrias\" count=\"1\" rel=\"link\">Acute porphyrias</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75216\" namespace=\"/drugs/colistimethate-sodium/tablet\" title=\"Tablet\" count=\"1\" rel=\"link\">Tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75245\" namespace=\"/drugs/colistimethate-sodium/powder-for-solution-for-injection\" title=\"Powder for solution for injection\" count=\"1\" rel=\"link\">Powder for solution for injection</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75259\" namespace=\"/drugs/colistimethate-sodium/inhalation-powder\" title=\"Inhalation powder\" count=\"1\" rel=\"link\">Inhalation powder</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75224\" namespace=\"/drugs/colistimethate-sodium/powder-for-nebuliser-solution\" title=\"Powder for nebuliser solution\" count=\"1\" rel=\"link\">Powder for nebuliser solution</xref>\n</links>\n</topic>",
    "id": "PHP3560",
    "outputclass": "drug",
    "rev": "1.11",
    "type": "drug",
    "namespace": "/drugs/colistimethate-sodium",
    "basename": "colistimethate-sodium",
    "title": "COLISTIMETHATE SODIUM",
    "interactants": [
        {
            "id": "bnf_int_190",
            "label": "Colistimethate Sodium"
        }
    ],
    "vtmid": "73074003",
    "drugClassification": [
        "Polymyxin antibacterials"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "synonyms": [
        "Colistin sulfomethate sodium"
    ],
    "drugAction": {
        "drugAction": [
            {
                "type": "drugAction",
                "textContent": "The polymyxin antibiotic, colistimethate sodium (colistin sulfomethate sodium), is active against Gram-negative organisms including Pseudomonas aeruginosa , Acinetobacter baumanii , and Klebsiella pneumoniae . It is not absorbed by mouth and thus needs to be given by injection for a systemic effect.",
                "html": "<p>The polymyxin antibiotic, <b>colistimethate sodium</b> (colistin sulfomethate sodium), is active against Gram-negative organisms including <ph outputclass=\"organism\">\n<i>Pseudomonas aeruginosa</i>\n</ph>, <ph outputclass=\"organism\">\n<i>Acinetobacter baumanii</i>\n</ph>, and <ph outputclass=\"organism\">\n<i>Klebsiella pneumoniae</i>\n</ph>. It is not absorbed by mouth and thus needs to be given by injection for a systemic effect.</p>"
            }
        ]
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Gram-negative infections resistant to other antibacterials, including those caused by Pseudomonas aeruginosa , Acinetobacter baumanii and Klebsiella pneumoniae",
                        "html": "Gram-negative infections resistant to other antibacterials, including those caused by <ph outputclass=\"organism\"> <i> <i>Pseudomonas aeruginosa</i> </i> </ph>, <ph outputclass=\"organism\"> <i> <i>Acinetobacter baumanii</i> </i> </ph> and <ph outputclass=\"organism\"> <i> <i>Klebsiella pneumoniae</i> </i> </ph>",
                        "organism": "Klebsiella pneumoniae"
                    }
                ],
                "specificity": {
                    "routes": [
                        "slow intravenous injection or intravenous infusion"
                    ],
                    "textContent": "By slow intravenous injection or by intravenous infusion",
                    "html": "By slow intravenous injection or by intravenous infusion",
                    "organism": "Klebsiella pneumoniae"
                },
                "adult": [
                    {
                        "textContent": "50 000&#8211;75 000 units/kg daily in 3 divided doses, to be administered into a totally implantable venous access device when giving via slow intravenous injection.",
                        "html": "<p>50&#8239;000&#8211;75&#8239;000&#8239;units/kg daily in 3 divided doses, to be administered into a totally implantable venous access device when giving via slow intravenous injection.</p>",
                        "ageGroup": "(body-weight up to 59 kg)"
                    },
                    {
                        "textContent": "1&#8211;2 million units every 8 hours, to be administered into a totally implantable venous access device when giving via slow intravenous injection.",
                        "html": "<p>1&#8211;2&#8239;million units every 8&#8239;hours, to be administered into a totally implantable venous access device when giving via slow intravenous injection.</p>",
                        "ageGroup": "(body-weight 60 kg and above)"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Adjunct to standard antibacterial therapy for Pseudomonas aeruginosa infection in cystic fibrosis",
                        "html": "Adjunct to standard antibacterial therapy for <ph outputclass=\"organism\"> <i> <i>Pseudomonas aeruginosa</i> </i> </ph> infection in cystic fibrosis",
                        "organism": "Pseudomonas aeruginosa"
                    }
                ],
                "specificity": {
                    "routes": [
                        "inhalation of powder"
                    ],
                    "textContent": "By inhalation of powder",
                    "html": "By inhalation of powder",
                    "organism": "Pseudomonas aeruginosa"
                },
                "adult": [
                    {
                        "textContent": "1&#8211;2 million units twice daily; increased to 2 million units 3 times a day, dose only to be increased for subsequent respiratory isolates of Pseudomonas aeruginosa .",
                        "html": "<p>1&#8211;2&#8239;million units twice daily; increased to 2&#8239;million units 3 times a day, dose only to be increased for subsequent respiratory isolates of <i> <i>Pseudomonas aeruginosa</i> </i>.</p>"
                    },
                    {
                        "textContent": "1.66 million units twice daily.",
                        "html": "<p>1.66&#8239;million units twice daily.</p>"
                    }
                ]
            }
        ]
    },
    "contraindications": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "Myasthenia gravis",
                "html": "Myasthenia gravis"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Acute porphyrias",
                "html": "<xref format=\"dita\" href=\"#PHP78608\" type=\"bookmark\" namespace=\"/treatment-summaries/acute-porphyrias\">Acute porphyrias</xref>",
                "references": [
                    {
                        "id": "PHP78608",
                        "label": "Acute porphyrias"
                    }
                ]
            }
        ],
        "cautionsOrContraindicationsWithRoutes": [
            {
                "type": "cautionsOrContraindicationsWithRoutes",
                "textContent": "severe haemoptysis&#8212;risk of further haemorrhage",
                "html": "severe haemoptysis&#8212;risk of further haemorrhage",
                "specificity": {
                    "textContent": "When used by inhalation",
                    "html": "When used by inhalation",
                    "routes": [
                        "inhalation"
                    ]
                }
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (polymyxins).",
                "html": "<p>Appendix 1 (polymyxins).</p>"
            }
        ]
    },
    "sideEffects": {
        "specific": {
            "frequencies": {
                "commonOrVeryCommon": [
                    {
                        "type": "sideEffectsWithRoutes",
                        "textContent": "bronchospasm",
                        "html": "bronchospasm",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "When used by inhalation",
                            "html": "When used by inhalation",
                            "routes": [
                                "inhalation"
                            ]
                        }
                    },
                    {
                        "type": "sideEffectsWithRoutes",
                        "textContent": "cough",
                        "html": "cough",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "When used by inhalation",
                            "html": "When used by inhalation",
                            "routes": [
                                "inhalation"
                            ]
                        }
                    },
                    {
                        "type": "sideEffectsWithRoutes",
                        "textContent": "dysphonia",
                        "html": "dysphonia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "When used by inhalation",
                            "html": "When used by inhalation",
                            "routes": [
                                "inhalation"
                            ]
                        }
                    },
                    {
                        "type": "sideEffectsWithRoutes",
                        "textContent": "nausea",
                        "html": "nausea",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "When used by inhalation",
                            "html": "When used by inhalation",
                            "routes": [
                                "inhalation"
                            ]
                        }
                    },
                    {
                        "type": "sideEffectsWithRoutes",
                        "textContent": "sore mouth",
                        "html": "sore mouth",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "When used by inhalation",
                            "html": "When used by inhalation",
                            "routes": [
                                "inhalation"
                            ]
                        }
                    },
                    {
                        "type": "sideEffectsWithRoutes",
                        "textContent": "Sore throat",
                        "html": "Sore throat",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "When used by inhalation",
                            "html": "When used by inhalation",
                            "routes": [
                                "inhalation"
                            ]
                        }
                    },
                    {
                        "type": "sideEffectsWithRoutes",
                        "textContent": "taste disturbances",
                        "html": "taste disturbances",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "When used by inhalation",
                            "html": "When used by inhalation",
                            "routes": [
                                "inhalation"
                            ]
                        }
                    },
                    {
                        "type": "sideEffectsWithRoutes",
                        "textContent": "vomiting",
                        "html": "vomiting",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "When used by inhalation",
                            "html": "When used by inhalation",
                            "routes": [
                                "inhalation"
                            ]
                        }
                    }
                ],
                "uncommon": [
                    {
                        "type": "sideEffectsWithRoutes",
                        "textContent": "hypersalivation",
                        "html": "hypersalivation",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "When used by inhalation",
                            "html": "When used by inhalation",
                            "routes": [
                                "inhalation"
                            ]
                        }
                    },
                    {
                        "type": "sideEffectsWithRoutes",
                        "textContent": "thirst",
                        "html": "thirst",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "When used by inhalation",
                            "html": "When used by inhalation",
                            "routes": [
                                "inhalation"
                            ]
                        }
                    }
                ],
                "rare": [
                    {
                        "type": "sideEffectsWithRoutes",
                        "textContent": "vasomotor instability",
                        "html": "vasomotor instability",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "With intravenous use",
                            "html": "With intravenous use",
                            "routes": [
                                "intravenous"
                            ]
                        }
                    }
                ],
                "notKnown": [
                    {
                        "type": "sideEffectsWithRoutes",
                        "textContent": "apnoea",
                        "html": "apnoea",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "With intravenous use",
                            "html": "With intravenous use",
                            "routes": [
                                "intravenous"
                            ]
                        }
                    },
                    {
                        "type": "sideEffectsWithRoutes",
                        "textContent": "confusion",
                        "html": "confusion",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "With intravenous use",
                            "html": "With intravenous use",
                            "routes": [
                                "intravenous"
                            ]
                        }
                    },
                    {
                        "type": "sideEffectsWithRoutes",
                        "textContent": "headache",
                        "html": "headache",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "With intravenous use",
                            "html": "With intravenous use",
                            "routes": [
                                "intravenous"
                            ]
                        }
                    },
                    {
                        "type": "sideEffectsWithRoutes",
                        "textContent": "muscle weakness",
                        "html": "muscle weakness",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "With intravenous use",
                            "html": "With intravenous use",
                            "routes": [
                                "intravenous"
                            ]
                        }
                    },
                    {
                        "type": "sideEffectsWithRoutes",
                        "textContent": "nephrotoxicity",
                        "html": "nephrotoxicity",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "With intravenous use",
                            "html": "With intravenous use",
                            "routes": [
                                "intravenous"
                            ]
                        }
                    },
                    {
                        "type": "sideEffectsWithRoutes",
                        "textContent": "neurotoxicity reported especially with excessive doses",
                        "html": "neurotoxicity reported especially with excessive doses",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "With intravenous use",
                            "html": "With intravenous use",
                            "routes": [
                                "intravenous"
                            ]
                        }
                    },
                    {
                        "type": "sideEffectsWithRoutes",
                        "textContent": "perioral paraesthesia",
                        "html": "perioral paraesthesia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "With intravenous use",
                            "html": "With intravenous use",
                            "routes": [
                                "intravenous"
                            ]
                        }
                    },
                    {
                        "type": "sideEffectsWithRoutes",
                        "textContent": "peripheral paraesthesia",
                        "html": "peripheral paraesthesia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "With intravenous use",
                            "html": "With intravenous use",
                            "routes": [
                                "intravenous"
                            ]
                        }
                    },
                    {
                        "type": "sideEffectsWithRoutes",
                        "textContent": "psychosis",
                        "html": "psychosis",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "With intravenous use",
                            "html": "With intravenous use",
                            "routes": [
                                "intravenous"
                            ]
                        }
                    },
                    {
                        "type": "sideEffectsWithRoutes",
                        "textContent": "rash",
                        "html": "rash",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "With intravenous use",
                            "html": "With intravenous use",
                            "routes": [
                                "intravenous"
                            ]
                        }
                    },
                    {
                        "type": "sideEffectsWithRoutes",
                        "textContent": "slurred speech",
                        "html": "slurred speech",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "With intravenous use",
                            "html": "With intravenous use",
                            "routes": [
                                "intravenous"
                            ]
                        }
                    },
                    {
                        "type": "sideEffectsWithRoutes",
                        "textContent": "vertigo",
                        "html": "vertigo",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "With intravenous use",
                            "html": "With intravenous use",
                            "routes": [
                                "intravenous"
                            ]
                        }
                    },
                    {
                        "type": "sideEffectsWithRoutes",
                        "textContent": "visual disturbances",
                        "html": "visual disturbances",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "With intravenous use",
                            "html": "With intravenous use",
                            "routes": [
                                "intravenous"
                            ]
                        }
                    }
                ]
            }
        },
        "advice": [
            {
                "type": "advice",
                "title": "Dose-related side-effects",
                "textContent": "The major adverse effects are dose-related neurotoxicity and nephrotoxicity.",
                "html": "<p>The major adverse effects are dose-related neurotoxicity and nephrotoxicity.</p>"
            }
        ]
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "specificity": {
                    "textContent": "When used by inhalation",
                    "html": "When used by <ph outputclass=\"route\">inhalation</ph>",
                    "routes": [
                        "inhalation"
                    ]
                },
                "textContent": "Clinical use suggests probably safe.",
                "html": "<p>Clinical use suggests probably safe.</p>"
            },
            {
                "type": "generalInformation",
                "specificity": {
                    "textContent": "With intravenous use",
                    "html": "With <ph outputclass=\"route\">intravenous</ph> use",
                    "routes": [
                        "intravenous"
                    ]
                },
                "textContent": "Use only if potential benefit outweighs risk.",
                "html": "<p>Use only if potential benefit outweighs risk.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Present in milk but poorly absorbed from gut; manufacturers advise avoid (or use only if potential benefit outweighs risk).",
                "html": "<p>Present in milk but poorly absorbed from gut; manufacturers advise avoid (or use only if potential benefit outweighs risk).</p>"
            }
        ]
    },
    "renalImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "specificity": {
                    "textContent": "With intravenous use",
                    "html": "With <ph outputclass=\"route\">intravenous</ph> use",
                    "routes": [
                        "intravenous"
                    ]
                },
                "textContent": "Reduce dose.",
                "html": "<p>Reduce dose.</p>"
            }
        ],
        "additionalMonitoring": [
            {
                "type": "additionalMonitoring",
                "specificity": {
                    "textContent": "With intravenous use",
                    "html": "With <ph outputclass=\"route\">intravenous</ph> use",
                    "routes": [
                        "intravenous"
                    ]
                },
                "textContent": "In renal impairment, monitor plasma colistimethate sodium concentration during parenteral treatment&#8212;consult product literature.\n\nRecommended &#8216;peak&#8217; plasma colistimethate sodium concentration (approx. 1 hour after intravenous injection or infusion) 5&#8211;15 mg/litre; pre-dose (&#8216;trough&#8217;) concentration 2&#8211;6 mg/litre.",
                "html": "<p>In renal impairment, monitor plasma colistimethate sodium concentration during parenteral treatment&#8212;consult product literature.</p><p>Recommended &#8216;peak&#8217; plasma colistimethate sodium concentration (approx. 1 hour after intravenous injection or infusion) 5&#8211;15&#8239;mg/litre; pre-dose (&#8216;trough&#8217;) concentration 2&#8211;6&#8239;mg/litre.</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "specificity": {
                    "textContent": "With intravenous use",
                    "html": "With <ph outputclass=\"route\">intravenous</ph> use",
                    "routes": [
                        "intravenous"
                    ]
                },
                "textContent": "Monitor renal function.",
                "html": "<p>Monitor renal function.</p>"
            },
            {
                "type": "patientParameters",
                "specificity": {
                    "textContent": "When used by inhalation",
                    "html": "When used by <ph outputclass=\"route\">inhalation</ph>",
                    "routes": [
                        "inhalation"
                    ]
                },
                "textContent": "Measure lung function before and after initial dose of colistimethate sodium and monitor for bronchospasm; if bronchospasm occurs in a patient not using a bronchodilator, repeat test using a bronchodilator before the dose of colistimethate sodium.",
                "html": "<p>Measure lung function before and after initial dose of colistimethate sodium and monitor for bronchospasm; if bronchospasm occurs in a patient not using a bronchodilator, repeat test using a bronchodilator before the dose of colistimethate sodium.</p>"
            }
        ]
    },
    "directionsForAdministration": {
        "directionsForAdministration": [
            {
                "type": "directionsForAdministration",
                "specificity": {
                    "textContent": "When used by inhalation",
                    "html": "When used by <ph outputclass=\"route\">inhalation</ph>",
                    "routes": [
                        "inhalation"
                    ]
                },
                "textContent": "Other inhaled drugs should be administered before colistimethate sodium.",
                "html": "<p>Other inhaled drugs should be administered before colistimethate sodium.</p>"
            },
            {
                "type": "directionsForAdministration",
                "specificity": {
                    "textContent": "With intravenous use",
                    "html": "With <ph outputclass=\"route\">intravenous</ph> use",
                    "routes": [
                        "intravenous"
                    ]
                },
                "textContent": "For intravenous infusion (Colomycin , Promixin ), give intermittently in Sodium chloride 0.9% (or Glucose 5% for Promixin brand only); dilute with 50 mL infusion fluid and give over 30 minutes.",
                "html": "<p>For <i>intravenous infusion</i> (<i>Colomycin</i>\n<tm tmtype=\"reg\"/>, <i>Promixin</i>\n<tm tmtype=\"reg\"/>), give intermittently in Sodium chloride 0.9% (or Glucose 5% for <i>Promixin</i>\n<tm tmtype=\"reg\"/> brand only); dilute with 50&#8239;mL infusion fluid and give over 30 minutes.</p>"
            }
        ]
    },
    "prescribingAndDispensingInformation": {
        "prescribingAndDispensingInformation": [
            {
                "type": "prescribingAndDispensingInformation",
                "textContent": "Colistimethate sodium is included in some preparations for topical application.",
                "html": "<p>Colistimethate sodium is included in some preparations for topical application.</p>"
            }
        ]
    },
    "patientAndCarerAdvice": {
        "generalPatientAdvice": [
            {
                "type": "generalPatientAdvice",
                "specificity": {
                    "textContent": "When used by inhalation",
                    "html": "When used by <ph outputclass=\"route\">inhalation</ph>",
                    "routes": [
                        "inhalation"
                    ]
                },
                "textContent": "Patient should be advised to rinse mouth with water after each dose of dry powder inhalation.",
                "html": "<p>Patient should be advised to rinse mouth with water after each dose of dry powder inhalation.</p>"
            }
        ]
    },
    "nationalFunding": {
        "niceTechnologyAppraisals": [
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA276",
                        "label": "www.nice.org.uk/TA276"
                    }
                ],
                "fundingIdentifier": "NICE TA276",
                "textContent": "Colistimethate sodium by dry powder inhalation for pseudomonal lung infection in cystic fibrosis (March 2013) Colistimethate sodium dry powder for inhalation is recommended for chronic pulmonary infection caused by Pseudomonas aeruginosa in patients with cystic fibrosis who would benefit from continued treatment, but do not tolerate the drug in its nebulised form. The manufacturer must provide colistimethate sodium dry powder for inhalation at the discount agreed as part of the patient access scheme to primary, secondary and tertiary care in the NHS. Patients currently receiving colistimethate sodium dry powder for inhalation can continue treatment until they and their clinician consider it appropriate to stop.\n\nwww.nice.org.uk/TA276",
                "html": "<p outputclass=\"title\">Colistimethate sodium by dry powder inhalation for pseudomonal lung infection in cystic fibrosis (March 2013)</p> <p>Colistimethate sodium dry powder for inhalation is recommended for chronic pulmonary infection caused by <ph outputclass=\"organism\"> <i>Pseudomonas aeruginosa</i> </ph> in patients with cystic fibrosis who would benefit from continued treatment, but do not tolerate the drug in its nebulised form. The manufacturer must provide colistimethate sodium dry powder for inhalation at the discount agreed as part of the patient access scheme to primary, secondary and tertiary care in the NHS. Patients currently receiving colistimethate sodium dry powder for inhalation can continue treatment until they and their clinician consider it appropriate to stop.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA276\">www.nice.org.uk/TA276</xref>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ],
        "availableForms": {
            "before": "Forms available from special-order manufacturers include",
            "forms": [
                "ear drops",
                "oral solution"
            ]
        }
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP75216",
                "label": "Tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP75245",
                "label": "Powder for solution for injection",
                "type": "medicinalForm"
            },
            {
                "id": "PHP75259",
                "label": "Inhalation powder",
                "type": "medicinalForm"
            },
            {
                "id": "PHP75224",
                "label": "Powder for nebuliser solution",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78467",
                "label": "Respiratory system",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78557",
                "label": "Eye",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_190",
                "label": "Colistimethate Sodium",
                "type": "interaction"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78608",
                "label": "Acute porphyrias",
                "type": "treatmentSummary"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP75216",
                "label": "Tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP75245",
                "label": "Powder for solution for injection",
                "type": "medicinalForm"
            },
            {
                "id": "PHP75259",
                "label": "Inhalation powder",
                "type": "medicinalForm"
            },
            {
                "id": "PHP75224",
                "label": "Powder for nebuliser solution",
                "type": "medicinalForm"
            }
        ]
    }
}